Industry
Vivacelle Bio
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
1 recruiting
Enrollment Performance
Analytics
Phase 3
1(50.0%)
Phase 2
1(50.0%)
2Total
Phase 3(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT06072430Phase 3Recruiting
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
Role: lead
NCT04257136Phase 2Unknown
VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients
Role: lead
All 2 trials loaded